These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 30069760)
1. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. Grüllich C Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760 [TBL] [Abstract][Full Text] [Related]
2. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Grüllich C Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794 [TBL] [Abstract][Full Text] [Related]
3. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Krajewska J; Olczyk T; Jarzab B Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165 [TBL] [Abstract][Full Text] [Related]
4. Cabozantinib for the treatment of renal cell carcinoma. Escudier B; Lougheed JC; Albiges L Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047 [TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946 [TBL] [Abstract][Full Text] [Related]
6. Cabozantinib in Thyroid Cancer. Fallahi P; Ferrari SM; Di Bari F; Materazzi G; Benvenga S; Miccoli P; Antonelli A Recent Pat Anticancer Drug Discov; 2015; 10(3):259-69. PubMed ID: 26152149 [TBL] [Abstract][Full Text] [Related]
7. [Cabozantinib: Mechanism of action, efficacy and indications]. Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875 [TBL] [Abstract][Full Text] [Related]
8. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. Santoni M; Iacovelli R; Colonna V; Klinz S; Mauri G; Nuti M Expert Rev Anticancer Ther; 2021 Sep; 21(9):1029-1054. PubMed ID: 34445927 [TBL] [Abstract][Full Text] [Related]
10. Cabozantinib in genitourinary malignancies. Zhang T; Park SE; Hong C; George DJ Future Oncol; 2017 Apr; 13(8):755-765. PubMed ID: 27842445 [TBL] [Abstract][Full Text] [Related]
11. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ; Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544 [TBL] [Abstract][Full Text] [Related]
12. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. Osanto S; van der Hulle T Ther Adv Urol; 2018 Mar; 10(3):109-123. PubMed ID: 29662541 [TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. Desai A; Small EJ Future Oncol; 2019 Jul; 15(20):2337-2348. PubMed ID: 31184937 [TBL] [Abstract][Full Text] [Related]
14. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. Tannir NM; Schwab G; Grünwald V Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252 [TBL] [Abstract][Full Text] [Related]
15. Cabozantinib for the treatment of kidney cancer. Abdelaziz A; Vaishampayan U Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552 [TBL] [Abstract][Full Text] [Related]
16. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062 [TBL] [Abstract][Full Text] [Related]
17. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412 [TBL] [Abstract][Full Text] [Related]